Vernalis plc is a research and development-stage pharmaceutical company. Vernalis has one marketed product and a portfolio of development and drug discovery programmes. Vernalis has nine active collaborations, four covering programmes in pre-clinical through to Phase II development and four active drug discovery collaborations. Its commercial pipeline includes CCP-01, CCP-05, CCP-06, CCP-07 and CCP-08. The Company operates in the United Kingdom, Rest of Europe, North America and Rest of the World. Frovatriptan is a selective 5-HT1B/1D receptor agonist approved as an acute oral treatment for migraine headache and its associated symptoms. It is a prescription drug, triptans, which used for the treatment of migraine. The Company has licensed frovatriptan marketing rights to Menarini for Europe, Central America and Brazil, to Endo for the United States, and to SK Chemicals for South Korea. Teva Neuroscience Canada markets frovatriptan in Canada under a sub-license from Endo.